Abstract
INTRODUCTION: Bevacizumab, a vascular endothelial growth factor inhibitor, is used off-label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right-sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
AIM: To report the experience of treatment with bevacizumab within European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN) centres.
METHOD: A retrospective analysis of the usage, availability, efficacy and safety in HHT patients treated with bevacizumab in European VASCERN centres.
RESULTS: A total of 151 patients received treatment with bevacizumab in European VASCERN centres. Most patients were treated in Denmark, France and the Netherlands. There was an improvement in haemoglobin with a mean increase of 2.9 g/dL (95% confidence interval 2.4, 3.6) and significant reduction in the number of red blood cell transfusions. Cardiac output was measured and improved in 85% of patients treated for high output cardiac failure in relation to severe HAVM. No severe adverse events were recorded, but 70 patients experienced at least one adverse event.
CONCLUSION: Although this is a retrospective study, we demonstrated convincing efficacy of bevacizumab in the treatment of patients with HHT, with a good risk-benefit balance.
| Original language | English |
|---|---|
| Pages (from-to) | 535-544 |
| Number of pages | 10 |
| Journal | British Journal of Clinical Pharmacology |
| Volume | 92 |
| Issue number | 2 |
| Early online date | 23 Sept 2025 |
| DOIs | |
| Publication status | Published - Feb 2026 |
Keywords
- VASCERN
- bevacizumab
- hereditary haemorrhagic telangiectasia
Fingerprint
Dive into the research topics of 'Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver